Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 8/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6344896 | 0.86 | PNP (0.75) | PNP | |
| SCHEMBL6340397 | 0.86 | PNP (0.75) | PNP | |
| SCHEMBL9073768 | 0.86 | PNP (0.75) | PNP | |
| SCHEMBL6351801 | 0.85 | PNP (0.76) | PNP | |
| SCHEMBL6343588 | 0.85 | PNP (1.00) | PNP | |
| SCHEMBL6341905 | 0.84 | PNP (1.00) | PNP | |
| SCHEMBL8801293 | 0.83 | PNP (0.71) | PNP | |
| SCHEMBL6345687 | 0.83 | PNP (0.71) | PNP | |
| SCHEMBL9050580 | 0.83 | PNP (0.71) | PNP | |
| SCHEMBL6345179 | 0.80 | PNP (0.81) | PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6946554-B2 | Process for the preparation of 9-deazaguanine derivatives | BIOCRYST PHARMACEUTICALS, INC. (US) | 2005-09-20 | — | — | US | disclosed |
| US-20040254181-A1 | Process for the preparation of 9-deazaguanine derivatives | BIOCRYST PHARMACEUTICALS, INC. | 2004-12-16 | — | — | US | disclosed |
| EP-0460116-B1 | 9-SUBSTITUTED-8-UNSUBSTITUTED-9-DEAZAGUANINES | BIOCRYST PHARM INC (US) | 1997-08-27 | — | — | EP | disclosed |
| US-5650511-A | MULTISTAGE REACTION OF ALDEHYDE OR KETONE WITH NITRILE GROUP TO FORM ENAMINE, REACTION OF ENAMINE WITH BASE TO FORM PYRROLE, THEN REACTION | BIOCRYST PHARMACEUTICALS, INC. (US) | 1997-07-22 | — | — | US | disclosed |
| US-5565463-A | PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 1996-10-15 | — | — | US | disclosed |
| EP-0460116-A4 | 9-SUBSTITUTED-8-UNSUBSTITUTED-9-DEAZAGUANINES | — | 1992-05-13 | — | — | EP | disclosed |
| EP-0460116-A1 | 9-SUBSTITUTED-8-UNSUBSTITUTED-9-DEAZAGUANINES. | BIOCRYST (US) | 1991-12-11 | — | — | EP | disclosed |
| WO-1990010631-A1 | 9-SUBSTITUTED-8-UNSUBSTITUTED-9-DEAZAGUANINES | BIOCRYST (US) | 1990-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254181-A1 | Process for the preparation of 9-deazaguanine derivatives | ALKBH3, ALKBH2, ALKBH1 | PNP 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.